News
Research presented at ASCO 2025 highlighted potential treatments for patients with newly diagnosed and relapsed or refractory ...
Adding lurbinectedin to atezolizumab as first-line maintenance improved PFS and OS in patients with ES-SCLC in the phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback